Beyond Air reports preliminary Q3 revenue of $2.3 million
Beyond Air Inc. (XAIR) reported preliminary Q3 2026 revenue of $2.3M, up 30% QoQ and 27% YoY, its highest quarterly revenue. The growth was driven by its LungFit PH system. The company reaffirmed its 2026 revenue guidance of $8M and 2027 guidance of $16M-$18M, pending FDA approval for its second-generation system. Final results are expected in November 2026.
How this was made
The 30-second read
Why it matters
The preliminary revenue release provides the first quantitative update for Q3, confirming growth momentum and reaffirming guidance for 2026‑2027.
Market read
Microcap earnings‑type news; may trigger short‑term price movement but limited broader market impact.
What to watch
Future FDA approval of the second‑generation system could materially change the outlook, but is uncertain.
Background
Beyond Air develops nitric‑oxide delivery devices for neonatal respiratory failure and other indications.
Ticker impact
Beyond Air reported preliminary Q3 revenue of $2.3M, a 30% increase YoY and its highest ever quarter.
potential upward pressure as investors price in stronger-than-expected revenue
The new revenue figure is the first public disclosure and exceeds prior quarters, which may attract buying interest.
Market effects
Shows growing adoption of nitric‑oxide medical devices, modestly bullish for the niche med‑tech sector.
Limited to U.S. biotech investors; no broader regional effect.
Low global relevance given the company's small size and niche market.
Counterpoint
Revenue remains tiny; the stock may still be overvalued despite the growth rate.
Key entities
- companyBeyond Air Inc.
Medical device and biopharmaceutical company focused on nitric‑oxide technology.
